Molomics advances the search for structurally novel small molecule therapeutics by Artificial Intelligence (AI) through integrating it with Human Collective Intelligence (HCI). As molecules are designed collaboratively in silico between machine and humans, we expect that our drug candidates are more efficacious and safer, increasing the success rates in clinical development.
It is very challenging to determine highly effective and safe therapeutics. Molomics Technology overcomes this challenge by integrating Humans Collective Intelligence (HCI) of teams with Artificial Intelligence (AI) to collaboratively design high potential drug candidates with diverse structures in real-time. The process generates quality drug information by machine learning methods and human knowledge to come up with optimal drug candidates.
Artificial Intelligence
(e.g. Machine Learning)
Human Intelligence
Consensus Decision Making
Molomics principal focus is Parkinson's Disease (PD). Current programs address Levodopa Induced Dyskinesia (LID). Strategies related to GPCRs (G Protein-Coupled Receptors) like allosteric modulation are applied in drug discovery and development.
Our drug discovery programs advance through three phases: the Feasibility Study, the Drug Design Phase and a partial Preclinical Analysis. We work with research institutes and industry partners like biotech and pharma to unlock new opportunities and to assure the design of efficacious and safer drugs.
Molomics wants to partner with selected biotechs or pharma companies in their disease area of interest. Molomics drug design approach, driven by its proprietary technology, is further re-inforced by state of the art project management:
We can address Multiple Biological Targets but also Phenotypic Screens
We determine a Success Probability of each project
Projects are based on Milestones
Track Project Advances in real-time through Molomics Technology
Include your Specialists with their Capabilities, Knowledge and Logic
We are open to partner our in-house Parkinson drug discovery programs in their advanced development stages.
Please feel free to contact us
